relapsing-remitting MS

I Think, Therefore I Am More Than My Mental Fatigue

ā€œA river cuts through rock not because of its power, but because of its persistence.ā€ ā€” James N. Watkins Fatigue is arguably the most disruptive symptom of multiple sclerosis (MS). At least it is for me. It has an awful lot to answer for. And it will.

Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study…

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the…

Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial

Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, anĀ experimental oral BTK inhibitor (BTKi) now being tested in people with relapsing-remitting multiple sclerosis (RRMS) in a Phase 2 clinical trial. Under the terms of the agreement, Biogen will have…

Dosing Begins in Trial of Anokion’s ANK-700 for RRMS

A Phase 1 clinical trial investigating ANK-700 as a means to restore immune tolerance to myelin in people multiple sclerosis (MS) has begun dosing participants. Currently recruiting at a single site in Tennessee, the trial (NCT04602390) is expected to enroll up to 40 patients with relapsing-remitting…

Health Canada OKs Self-administered Kesimpta for Adults With Active RRMS

Health Canada has approvedĀ Kesimpta (ofatumumab) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active disease, as defined by clinical and imaging features. In contrast with other B-cell-targeting therapies used in MS, patients can self-administer a precise dose of Kesimpta at home using the Sensoready…

Aubagio Lowers Relapse Rate in RRMS Patients, Real-world Observational Study Shows

In clinical practice, relapse events dropped by roughly half over a four-year period inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients treated withĀ Aubagio (teriflunomide), a real-world study reports. The study, ā€œReal-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study,ā€ also examined patients’ perspectives in…

Anti-LINGO-1: All You Need to Know

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…